Ticlopidine-induced lupus

Area of Science:

• Rheumatology
• Pharmacology
• Internal Medicine

Background:

• Ticlopidine is a thienopyridine antiplatelet agent prescribed for stroke and vascular event prevention.
• Drug-induced lupus erythematosus (DILE) is a recognized adverse effect of various medications.
• Identifying drug triggers for lupus is crucial for patient management and understanding pathogenesis.

Purpose of the Study:

• To report three cases of lupus-like illness potentially induced by ticlopidine.
• To highlight the clinical features and diagnostic considerations for ticlopidine-induced lupus.
• To emphasize the importance of drug withdrawal for symptom resolution.

Main Methods:

• Case series describing three patients who developed lupus-like symptoms after ticlopidine initiation.
• Clinical evaluation including physical examination, laboratory tests (antinuclear antibodies, antihistone antibodies), and assessment of symptom progression.
• Monitoring of patient response to ticlopidine discontinuation.

Main Results:

• All three patients presented with fever, rash, arthritis, and laboratory evidence of autoimmunity (positive antinuclear and antihistone antibodies).
• Symptoms appeared shortly after starting ticlopidine and gradually resolved upon drug cessation.
• Renal involvement was noted in one patient, which also improved after ticlopidine withdrawal.

Conclusions:

• Ticlopidine can be a potential trigger for drug-induced lupus, presenting with characteristic lupus-like features.
• Clinical suspicion supported by laboratory findings (fever of unknown origin, musculoskeletal, hematologic abnormalities) is key for diagnosis.
• Discontinuation of ticlopidine leads to slow but complete resolution of symptoms in most cases.